Cancer immunotherapy

Immunotherapy
#Cancer immunotherapy #CRISPR #Francis Crick Institute #Immune response

Immune cell behaviour challenges traditional classification 

Researchers at the Francis Crick Institute, King’s College London and Complutense University of Madrid have shown that γδ T cells use adaptive immune receptors to drive rapid, innate-like responses to tissue stress, inflammation and cancer.  Researchers have long divided the immune system into two broad arms: innate… Read More

#News

Immunotherapy
#Cancer immunotherapy #Cervical cancer #National Institute for Health and Care Excellence (NICE) #Regeneron Pharmaceuticals

NICE recommends immunotherapy to treat cervical cancer 

The National Institute for Health and Care Excellence (NICE) has recommended cemiplimab for the treatment of advanced cervical cancer.  The immunotherapy, developed by biotechnology company Regeneron, has been recommended in England and Wales to treat recurrent or metastatic cervical cancer that has progressed on or after platinum-based chemotherapy in adults.   This… Read More

#News #Regulatory

Cancer immunotherapy
#Asgard Therapeutics #Biotech #Cancer immunotherapy #Tumour biology

Gene-based immunotherapy could reprogramme tumour cells 

Biotechnology company Asgard Therapeutics is set to announce preclinical results showing its gene-based cancer immunotherapy could reprogramme tumour cells.  The company will present data on AT-108, a first-in-class, off-the-shelf cancer immunotherapy, in an oral presentation at the ASGCT Annual Meeting, held from 11-15 May in Boston,… Read More

#News

#AC Immune #Alzheimer's #Cancer Grand Challenges #Cancer immunotherapy #Childhood cancer #Clinical trial #Eli Lilly #FDA #Francis Crick Institute #Genetics #GLP-1 #Neurodevelopmental disorders

DDW Highlights: 14 April 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, researchers discovered how genetic mutations cause a previously unknown recessive condition. Elsewhere, Eli… Read More

#Podcasts

#AC Immune #Alzheimer's #Cancer Grand Challenges #Cancer immunotherapy #Childhood cancer #Clinical trial #Eli Lilly #FDA #Francis Crick Institute #Genetics #GLP-1 #Neurodevelopmental disorders

This week in Drug Discovery (6 – 10 April) 

News round-up for 6 – 10 April by Bruno Quinney, Content Team at DDW.  This week, researchers have discovered how genetic mutations cause a previously unknown recessive condition. Elsewhere, Lilly has made the headlines for both an approved drug and a drug collaboration.  The top stories: … Read More

#News

Cancer research
#Cancer Grand Challenges #Cancer immunotherapy #CAR-T #Childhood cancer #Clinical trial

Trial to test CAR T-cell therapies as childhood cancer cures 

A first-of-its-kind trial has launched to explore whether personalised CAR T-cell immunotherapy could treat childhood cancers. The clinical trial, taking place in the UK and US, has enrolled a group of 60 children with cancer and offered them access to personalised investigational therapies. Researchers hope these investigational therapies… Read More

#Cancer Research #Editor's Choice #News

#Alzheimer's #Bacteria #Brain cancer #Cancer immunotherapy #Clinical trial #Drug resistance #Fast Track designation #FDA #Gene therapy #Life sciences #Melanoma #Siren Biotechnology #UK government #University of Sydney

DDW Highlights: 10 February 2026

The latest episode of the DDW Highlights Podcast is now available to listen to below. DDW’s Bruno Quinney narrates five key stories of the previous week to keep DDW subscribers up-to-date on the latest industry news. Last week, innovative therapies showed the way to more effective cancer treatments. Elsewhere, how can… Read More

#Podcasts

#Alzheimer's #Bacteria #Brain cancer #Cancer immunotherapy #Clinical trial #Drug resistance #Fast Track designation #FDA #Gene therapy #Life sciences #Melanoma #Siren Biotechnology #UK #UK government #University of Sydney

This week in Drug Discovery (2 – 6 February) 

News round-up for 2 – 6 February by Bruno Quinney, Content Team at DDW.  This week in DDW, innovative therapies could pave the way to more effective cancer treatments. Elsewhere, how can brain function be improved in Alzheimer’s patients?  The top stories:      Immunotherapy before surgery… Read More

#News

Immunotherapy
#Cancer immunotherapy #Clinical trial #Melanoma

Immunotherapy before surgery could better treat melanoma 

Administering immunotherapy to melanoma patients before surgery could shrink tumours and improve quality of life.  New research, published in Nature Cancer, shows that 71% of desmoplastic melanoma patients who received the immunotherapy drug pembrolizumab before surgery had no detectable cancer remaining at the time of surgery.   Administering… Read More

#Cancer Research #News

B-cells in multiple myeloma
#Cancer immunotherapy #Clinical development #CNS #Essential Pharma #Rare disease

New podcast: From established medicines to rare disease innovation

In the In Conversation With series, a part of the free DDW podcast, DDW speaks with members of the drug discovery industry about their work and how it helps turn science into business.    In this episode, Megan Thomas is in conversation with Emma Johnson, CEO… Read More

#News

Cancer research
#ASCO #Cancer immunotherapy #Cancer research #Cell therapy #Oncology #Precision medicine #Therapeutics

Expert commentary from ASCO 2025

This year’s American Society of Clinical Oncology (ASCO) Annual Meeting took place at the McCormick Place Convention Center in Chicago from 30 May to 3 June 2025. DDW’s Megan Thomas collected commentary from industry experts in attendance. CCR8 therapies gain clinical significance Stephan Schann is Chief Scientific Officer at Domain… Read More

#Cancer Research #Exclusive Content

#Antibody drug conjugate (ADC) #Cancer immunotherapy #Cancer vaccine #Cell therapy #Immunotherapy

New DDW Highlights podcast: 20 January 2025

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. This week we have seen a number of positive announcements related to the early… Read More

#News

#Antibody drug conjugate (ADC) #Cancer immunotherapy #Cancer vaccine #Cell therapy #Immunotherapy

This week in drug discovery (13-17 January) 

News round-up for 13-17 January by DDW Senior Digital Content Editor Diana Spencer. This week we have seen a number of positive announcements related to the early clinical and preclinical development of immunotherapies, including an islet cell therapy for diabetes, an antibody-drug conjugate and a CAR-T therapy for… Read More

#News

B-cells in multiple myeloma
#Cancer immunotherapy #FDA #MAIA Biotechnology #Paediatrics #Rare disease

Telomere-targeting agent granted Rare Pediatric Disease designation

The US Food and Drug Administration (FDA) has designated MAIA Biotechnology’s immunotherapy THIO for the treatment of paediatric-type diffuse high-grade gliomas (PDHGG) as a drug for a rare paediatric disease. “THIO is a versatile anti-cancer agent that has demonstrated positive results in multiple difficult to treat cancer types, including paediatric… Read More

#Cancer Research #News

#Cancer immunotherapy #Events #Immunotherapy #Oncology

New DDW Highlights podcast: 18 November 2024

The latest episode of the DDW Highlights podcast is now available to listen to and watch below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates. With the Society for Immunotherapy of Cancer (SITC) 2024 taking place in Houston… Read More

#News